Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors
NCT07174661 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2025-12-18
Summary
This clinical trial studies whether educational tools work to improve early advance care planning (ACP) in adolescents and young adults (AYAs) with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and high-grade brain tumors. The incidence of AYA cancers is on the rise with approximately 90,000 new diagnoses yearly in the United States. Cancer remains the leading cause of disease-related death among AYAs, which could be due to patients having more advanced disease at presentation. It is recommended that AYAs begin ACP conversations at the start of treatment. ACP includes clarifying goals of care, discussions about end-of-life preferences, and completing a legal document that states the treatment or care a person wishes to receive or not receive if they become unable to make medical decisions (advance directive). The educational tools in this study include an early ACP educational video featuring AYAs with cancer and an ACP appointment geared for AYAs. Patients can access and watch the educational video at home prior to their scheduled ACP appointment. During the ACP appointment, a tailored ACP guide made specifically for AYAs is reviewed and questions regarding ACP are answered. This may help to introduce the importance of key ACP concepts, which may improve early ACP in AYAs with advanced solid tumors and high-grade brain tumors.
Conditions
- Advanced Malignant Solid Neoplasm
- Malignant Brain Neoplasm
- Recurrent Advanced Malignant Solid Neoplasm
Interventions
- BEHAVIORAL
-
Advance Care Planning
Attend ACP appointment
- OTHER
-
Educational Intervention
Watch on-demand early ACP educational video
- OTHER
-
Electronic Health Record Review
Ancillary studies
- OTHER
-
Survey Administration
Ancillary studies
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Allison C. Rosenthal, DO · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 39 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-02
- Primary Completion
- 2027-06-30
- Completion
- 2027-06-30
Countries
- United States
Study Locations
More Related Trials
-
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
NCT04643418 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
NCT04645069 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial of PBI-05204 in Advanced Cancer Patients
NCT00554268 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas
NCT01279603 ·Status: COMPLETED ·Phase: PHASE1
-
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
NCT04439227 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
NCT02551185 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
NCT02740985 ·Status: COMPLETED ·Phase: PHASE1
-
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
NCT00996060 ·Status: COMPLETED ·Phase: PHASE1
-
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
NCT06290388 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
NCT01021748 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
NCT02073994 ·Status: COMPLETED ·Phase: PHASE1
-
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
NCT04601402 ·Status: COMPLETED ·Phase: PHASE1
-
BMS-214662 in Treating Patients With Advanced Solid Tumors
NCT00004877 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT02807636 ·Status: COMPLETED ·Phase: PHASE3
-
Study of APR-1051 in Patients With Advanced Solid Tumors
NCT06260514 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
NCT02266745 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00096005 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298387 ·Status: COMPLETED ·Phase: PHASE1
-
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
NCT06365918 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005 ·Status: RECRUITING ·Phase: PHASE1
-
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
NCT02517398 ·Status: COMPLETED ·Phase: PHASE1